2 years ago

AMPLY Discovery Secures €1.6 Million Grant to Advance AI-Driven Drug Discovery

  • AMPLY Discovery, a Belfast-based techbio company, has secured over €1.6 million in grant funding from Innovate UK to develop new drug products using its AI-driven drug discovery platform

  • The company, a spin-out from Queen's University Belfast, was established in 2021 to commercialize the platform developed by researchers in the School of Biological Science at Queen's

  • AMPLY's technology leverages the power of evolution to discover new medicines from nature's untapped reservoir, focusing on cures for cancer, metabolic, and infectious diseases

  • The company is currently working on two flagship R&D programs: one focused on RNAi therapies for highly genetically mediated cancers and another focused on inhaled antimicrobial therapies to fight multi-drug resistant (MDR) lung infections.

      • ProblemTechnology

      "Discovering new drugs is a long and expensive process, often taking years and costing billions of dollars. This makes it difficult for smaller companies to develop new treatments for complex diseases."

      Solution

      "AMPLY Discovery is developing an AI-driven drug discovery platform that uses synthetic biology and machine learning to accelerate the process of finding new drugs. This platform can be used to discover new treatments for a wide range of diseases, including cancer, metabolic disorders, and infectious diseases."

      Covered on